The demand for drug eruptions treatment in USA is projected to grow from USD 1.7 billion in 2026 to USD 3.3 billion by 2036, at a CAGR of 6.2%. Corticosteroids will dominate with a 28.0% market share, while oral will lead the route of administration segment with a 40.0% share.